Thane  Wettig net worth and biography

Thane Wettig Biography and Net Worth

Insider of FibroGen
Thane Wettig serves as Chief Commercial Officer of the Company. Mr. Wettig most recently served as Chief Commercial Officer and Metabolic Franchise Head at Intarcia Therapeutics. Prior to joining Intarcia in 2018, Thane spent more than 27 years at Lilly in roles of increasing responsibility, where he served as Vice President of Global Marketing, Strategy and Alliance Management for Lilly Diabetes, leading the development and launch of multiple blockbuster diabetes medicines during a period of unprecedented growth of Lilly's diabetes business. Thane also played an integral role in the design and management of Lilly's highly successful diabetes alliance.

What is Thane Wettig's net worth?

The estimated net worth of Thane Wettig is at least $1.02 million as of March 7th, 2024. Mr. Wettig owns 470,178 shares of FibroGen stock worth more than $1,020,286 as of March 19th. This net worth estimate does not reflect any other investments that Mr. Wettig may own. Additionally, Mr. Wettig receives a salary of $807,350.00 as Insider at FibroGen. Learn More about Thane Wettig's net worth.

How old is Thane Wettig?

Mr. Wettig is currently 59 years old. There are 4 older executives and no younger executives at FibroGen. The oldest executive at FibroGen is Dr. John J. Hunter Ph.D., Chief Scientific Officer, who is 61 years old. Learn More on Thane Wettig's age.

What is Thane Wettig's salary?

As the Insider of FibroGen, Inc., Mr. Wettig earns $807,350.00 per year. There are 2 executives that earn more than Mr. Wettig. The highest earning executive at FibroGen is Ms. Christine L. Chung, Senior Vice President of China Operations, who commands a salary of $1,270,000.00 per year. Learn More on Thane Wettig's salary.

How do I contact Thane Wettig?

The corporate mailing address for Mr. Wettig and other FibroGen executives is 409 ILLINOIS STREET, SAN FRANCISCO CA, 94158. FibroGen can also be reached via phone at (415) 978-1200 and via email at [email protected]. Learn More on Thane Wettig's contact information.

Has Thane Wettig been buying or selling shares of FibroGen?

During the last quarter, Thane Wettig has bought $95,500.00 in shares of FibroGen stock. Most recently, on Thursday, March 7th, Thane Wettig bought 50,000 shares of FibroGen stock. The stock was acquired at an average cost of $1.91 per share, with a total value of $95,500.00. Following the completion of the transaction, the chief executive officer now directly owns 470,178 shares of the company's stock, valued at $898,039.98. Learn More on Thane Wettig's trading history.

Who are FibroGen's active insiders?

FibroGen's insider roster includes Pat Cotroneo (CFO), Thomas Kearns, Jr. (Director), and Thane Wettig (Insider). Learn More on FibroGen's active insiders.

Are insiders buying or selling shares of FibroGen?

In the last year, FibroGen insiders bought shares 1 times. They purchased a total of 50,000 shares worth more than $95,500.00. In the last year, insiders at the biopharmaceutical company sold shares 18 times. They sold a total of 63,716 shares worth more than $1,014,059.35. The most recent insider tranaction occured on March, 7th when CEO Thane Wettig bought 50,000 shares worth more than $95,500.00. Insiders at FibroGen own 2.4% of the company. Learn More about insider trades at FibroGen.

Information on this page was last updated on 3/7/2024.

Thane Wettig Insider Trading History at FibroGen

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/7/2024Buy50,000$1.91$95,500.00470,178View SEC Filing Icon  
6/23/2023Sell791$16.53$13,075.23108,261View SEC Filing Icon  
6/7/2023Sell1,758$17.04$29,956.32111,395View SEC Filing Icon  
3/23/2023Sell905$18.71$16,932.55110,653View SEC Filing Icon  
12/23/2022Sell734$15.80$11,597.2089,163View SEC Filing Icon  
12/8/2022Sell382$15.79$6,031.7889,897View SEC Filing Icon  
8/26/2021Buy3,100$11.53$35,743.00View SEC Filing Icon  
See Full Table

Thane Wettig Buying and Selling Activity at FibroGen

This chart shows Thane Wettig's buying and selling at FibroGen by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

FibroGen Company Overview

FibroGen logo
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
Read More

Today's Range

Now: $2.17
Low: $1.95
High: $2.36

50 Day Range

MA: $1.69
Low: $0.75
High: $2.73

2 Week Range

Now: $2.17
Low: $0.33
High: $20.90

Volume

2,554,005 shs

Average Volume

2,808,177 shs

Market Capitalization

$214.33 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.66